BOLT BOLT
Company Profile ↓Company Overview
BOLT (BOLT) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 101.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $7.70M (+0.1% YoY); net profit $-33.38M.
- Trailing 12 Months Year-on-year growth — revenue +0.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 101.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 101.61% |
| 1 Year: | 0.07% |
Stock Price Performance
| 1 Year: | -29.72% |
| 6 Months: | -32.82% |
| 3 Months: | -15.24% |
| 1 Month: | -2.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.87 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 101.6% over 5 years.
CONS
- Trading 44.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.00K | 67.00K | - | - | 0 | 752.00K | 813.00K | 1.39M | 2.11M | 1.83M | 1.43M | 2.53M | 5.27M | 1.27M | 1.14M | 1.22M | 1.80M | 2.17M | 26.00K |
| Operating Income | -8.74M | -11.11M | -12.40M | -18.43M | -23.76M | -23.53M | -23.88M | -23.06M | -22.35M | -18.41M | -19.83M | -18.18M | -17.09M | -22.60M | -16.44M | -12.12M | -9.21M | -7.70M | -7.60M |
| Net Income | -8.63M | -11.06M | -10.00M | -24.45M | -23.59M | -23.39M | -23.68M | -22.66M | -21.76M | -16.98M | -18.06M | -16.26M | -10.81M | -21.20M | -15.18M | -11.04M | -8.56M | -7.14M | -7.24M |
| Diluted EPS | - | - | - | - | - | -0.63 | -0.64 | -0.61 | -0.58 | -0.45 | -0.48 | -0.43 | -0.28 | -11.12 | -7.93 | -5.76 | -4.46 | -3.72 | -4.31 |
| R&D Expense | 6.79M | 9.17M | 9.54M | 14.13M | 19.71M | 19.34M | 18.39M | 18.92M | 18.97M | 14.62M | 15.64M | 14.95M | 16.53M | 15.43M | 13.79M | 9.51M | 7.50M | 6.54M | 4.83M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 231.00K | 1.26M | 5.73M | 7.88M | 7.69M | 7.70M |
| Operating Income | -49.18M | -92.79M | -90.32M | -76.20M | -73.05M | -36.11M |
| Net Income | -60.73M | -98.59M | -88.10M | -69.20M | -63.12M | -33.38M |
| Diluted EPS | - | -2.97 | -2.36 | -1.83 | -33.06 | -17.85 |
| R&D Expense | 40.36M | 75.66M | 73.12M | 61.54M | 57.47M | 28.53M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 46.54M | 307.72M | 227.81M | 159.78M | 99.63M | 56.75M |
| Total Equity | -45.85M | -104.95M | 250.12M | 171.51M | 112.74M | 57.20M | 26.50M |
| Cash & Equivalents | - | 5.54M | 27.38M | 9.24M | 10.81M | 7.21M | 11.70M |
| Total Liabilities | - | 46.19M | 57.60M | 56.30M | 47.04M | 42.43M | 30.24M |
| Current Liabilities | - | 11.26M | 21.33M | 23.12M | 20.46M | 15.86M | 8.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -47.31M | - | -76.50M | -69.53M | -61.29M | -39.85M |
| Investing Cash Flow | -20.59M | - | 57.86M | 71.04M | 57.58M | 44.30M |
| Financing Cash Flow | 39.60M | - | 503.00K | 253.00K | 108.00K | 19.00K |
| Capital Expenditure | -3.26M | - | -1.95M | -206.00K | -41.00K | -72.00K |
| Free Cash Flow | -50.57M | - | -78.46M | -69.73M | -61.33M | -39.92M |
| Net Change in Cash | - | - | -18.14M | 1.77M | -3.60M | 4.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -21,290.9% | -7,364.1% | -1,576.6% | -967.4% | -949.9% | -469.3% |
| Net Margin % | -26,289.2% | -7,824.7% | -1,537.8% | -878.6% | -820.8% | -433.7% |
| ROE % | 57.9% | -39.4% | -51.4% | -61.4% | -110.4% | -125.9% |
| ROCE % | -139.4% | -32.4% | -44.1% | -54.7% | -87.2% | -74.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BOLT
If You Invested $1,000 in Bolt Metals Corp (PCRCF) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTFBxdXhEcXJpLWtkQXBwVEx4U3dZX0Z6bWdrNGIyVXppOUxSWFdMdVpLbm40Z1NLTVdadlN6VFZhZ0k1aHVnRzhFRVd6ZGV1M1FadWtqUmNDOG0taGlwd0N0Z1J3Y1lrZDRIZkdLYlVMOA?oc=5" target="_blank">If You Invested $…
BioLight Life Sciences Ltd. Revenue Breakdown – TASE:BOLT - TradingView
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE54bS1zLWVGUUJKZFlzMEEtY1czalU0b1dFWEhzek5NUXd5dW5YRS1OV3F5UDhFWVgxcDNsUHI0Z2FJajRxTFFFTDBjYjhIU21vNF9sd2NkV09RZ3BMdVBWUU1HQ2QyWXhHV1BUanRDMGd4RXRp?oc=5" target="_blank">BioLight Li…
WOOX Introduces the Elegante Hybrid Bolt Action Stock - Outdoor Wire
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNTkFBMkRhYzVHZkZHZDlCS0dwZWJtbVZ0S0NuTHk4V0hMNHdiMURZeE1kSzdzWG53aFp6dHh1SGpnVXhsSmRaaVdRZXctbkJQRXF2bjllanJ0N1o0QzJ0Q1Z4b092STJXWlc4NURrNXJ3THRtckNxbEIwWnB5ODJBYXFsb0hPSmI5TVh2RD…
Bolt CEO says he let go of his entire HR team for creating problems that didn’t exist: ‘Those problems disappeared when I let them go’ - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPX2syd1NRT2VqSk5seUhrc01aMlZPR2hiMG91Y2w4TWpjYm1tUmpHZEF6Njluc1VXYkk3c0ROeTBldl9LWVZsUXdScklfbWpHLUx6dWNYT1FVMHZBZkJteTJfVGlMNzRTeXRnTTd6YlZWT0RDMXNFZWpOOXFYVDZwZE9xbTVuYW9nQ2pJbE…
Bolt Projects Holdings Announces Delisting From Nasdaq and SEC Deregistration - Business Wire
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNeEtIcXJXS0wwSnlPV21ma0dwWHlyYUFtYjV6VGtZbWs5STFiWjN5TnZNeU5JSE11UnJwWU5mOExqR3ZUZld3UEYxcUpwMmVsSUYyeTIzTkhXVWNHaDB2a2FIbFlIZDNjNDVmRF9wb1FIOU1GQi15aDVEejQ1anBOSDBQRHFXaHA3a25wTz…
Bolt Biotherapeutics (BOLT) Slips 1.24% to $3.99; Resistance at $4.19 Caps Upside - Resistance Breakout Stocks - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQd1VsWHVRdWcxcnlSRHcydU9vOHhCRDhSeW5GMXpkdHQzdDVEbng3aFpVYzlfaEZjTVBycG5zSU52WUkyUElmQUpEbU96cDhLNTE2Vi1FNlRrMHpjN3c1YWNQR3ZFZE4xaTFzcGRaSXhtZ3d1elIxVXQ2X3M4SkdBNE9meHBoUXZZdndDQ1…
BOLT — Frequently Asked Questions
What is the current share price of BOLT?
As of 2026-08-05 17:25 PDT, BOLT trades at $3.95 on NASDAQ/NYSE. Its 52-week range is $3.78 to $7.09.
What is the P/E ratio of BOLT?
BOLT trades at a trailing price-to-earnings (P/E) ratio of -0.22.
What is the return on equity (ROE) of BOLT?
BOLT has a return on equity (ROE) of -125.92%. Its return on capital employed (ROCE) is -74.75%.
Is BOLT a good stock to buy?
This page provides a data-driven analysis of BOLT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.